Core Insights - TELA Bio, Inc. has appointed William Plovanic, CFA, to its Board of Directors, enhancing its leadership with expertise in capital markets and medical technology operations [1][3]. Group 1: Appointment Details - William Plovanic brings over 25 years of experience in capital markets, corporate strategy, and medical device operations [4][5]. - He currently serves as Managing Director of Healthcare Equity Research at Canaccord Genuity and has held C-level roles at Obalon Therapeutics from 2016 to 2021 [2][5]. Group 2: Company Strategy and Vision - TELA Bio focuses on innovative soft-tissue reconstruction solutions that prioritize the preservation and restoration of the patient's anatomy [7]. - The company aims to provide advanced, economically effective solutions that leverage the patient's natural healing response while minimizing long-term exposure to synthetic materials [7]. Group 3: Leadership Perspective - The CEO of TELA Bio, Antony Koblish, expressed confidence that Plovanic's experience will strengthen the company's strategy and drive long-term shareholder value [3]. - Plovanic stated his honor in joining TELA Bio at a pivotal stage, highlighting the company's leadership in redefining soft-tissue reconstruction [3].

Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions that optimize clinical outcomes by preserving and restoring the patient's own anatomy [2] - The company aims to provide advanced and economically effective solutions for surgeons, leveraging the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials [2] Upcoming Events - TELA Bio will participate in the Canaccord Genuity 45 Annual Growth Conference, with management scheduled to present on August 13, 2025, at 10:00 am ET [1] - Interested parties can access the live and archived webcast of the presentation at ir.telabio.com [1]

Core Viewpoint - TELA Bio, Inc. has appointed Jeffrey Blizard as President to enhance its leadership team and drive the next phase of growth in the medical technology sector, particularly in soft-tissue reconstruction solutions [1][2]. Leadership Changes - Jeffrey Blizard, previously on TELA Bio's Board of Directors, brings extensive industry experience and a successful track record from his role as Global Head of Surgical Sales at Abiomed, contributing to significant growth in that division [1][2]. - The CEO of TELA Bio, Antony Koblish, emphasized that Blizard's leadership will enhance the company's competitive edge and commercial performance in a dynamic market [2]. Company Overview - TELA Bio, Inc. is focused on innovative technologies for soft-tissue reconstruction, aiming to optimize clinical outcomes by preserving and restoring the patient's anatomy [3]. - The company is committed to providing advanced, economically effective solutions that leverage the patient's natural healing response while minimizing reliance on permanent synthetic materials [3].

Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions [2] - The company aims to optimize clinical outcomes by preserving and restoring the patient's own anatomy [2] - TELA Bio provides advanced, economically effective solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials [2] Upcoming Events - TELA Bio will participate in the 2025 Jefferies Global Healthcare Conference [1] - The management is scheduled to present at 11:05 am ET on June 5, 2025 [1] - Interested parties can access the live and archived webcast at ir.telabio.com [1]